88IV - PR Newswire Asia's news


Link Cell Therapies Initiates Clinical Dosing with Logic-Gated CAR-T Therapy, Expands Executive Leadership, and Upsizes Series A Financing to $90 Million – LNK001, an AND-gated CAR-T therapy targeting CAIX and ENPP3, is being evaluated in a Phase 1 study in advanced clear cell renal cell carcinoma at MD Anderson Cancer Center – ... 2026-09-28T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Jaypirca® (pirtobrutinib) Approved in China for a New Indication in Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) Across All Lines of Therapy SAN FRANCISCO and SUZHOU, China , Sept. 28, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, ... 2026-09-28T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
CityUHK researchers advance spatial omics to routine clinical use HONG KONG , Sept. 28, 2026 /PRNewswire/ -- Recently, spatial omics has become a powerful tool, enabling researchers to see not only what molecules are present in a tissue, but also where they are located ... 2026-09-28T Biotechnology Education Health Care/Hospital Higher Education
SOLA Biosciences Japan Receives AMED Grant to Advance SOL-257, Innovative Gene Therapy Aiming to Restore TDP-43 Function for ALS Patients TOKYO and BOSTON , Sept. 28, 2026 /PRNewswire/ -- SOLA Biosciences Japan GK ("SOLA Japan"), the wholly owned Japanese subsidiary of Boston-based SOLA Biosciences Inc. (together, "SOLA"), ... 2026-09-28T Biotechnology Health Care/Hospital Medical Equipment Medical/Pharmaceuticals
Akeso Announces First Patient Enrolled in Global Phase III Trial of Cadonilimab Versus Nivolumab in First-Line Gastric Cancer HONG KONG , Sept. 28, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that the first patient has been enrolled in COMPASSION-37 (AK104-311), a ... 2026-09-28T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Innovent Announces Expansion of Global Phase 3 MarsLight-11 Study of IBI363/TAK-928 (Alpha-biased IL-2/PD-1 Bispecific Fusion Protein) in Immunotherapy-Resistant NSCLC to Include Patients with Non-Squamous NSCLC SAN FRANCISCO and SUZHOU, China , Sept. 28, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, ... 2026-09-28T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
2026 IMS \| IASO Bio Presented FUCASO China Real-World Data - In a large China real-world study of 281 heavily pretreated, predominantly high-risk patients with relapsed/refractory plasma cell neoplasms, FUCASO achieved a 95.9% objective response rate, a 77.2% ... 2026-09-27T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
2026 IMS \| IASO Bio Presented First-in-Human Data of BCMA-Targeted In Vivo CAR-T Cell Therapy IASO206 — Late-breaking oral presentation of first-in-human data (LBA-11) showed that a single intravenous infusion of IASO206 generated functional BCMA CAR-T cells in vivo without lymphodepleting chemotherapy. ... 2026-09-27T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Second NRF2 Degrader Enters Clinical Development: Nutshell Therapeutics' NTS231 Received FDA IND Clearance SHANGHAI , Sept. 25, 2026 /PRNewswire/ -- Nutshell Therapeutics (Shanghai) Co., Ltd. ("Nutshell Therapeutics"), an innovative biotech company focused on AI-driven allosteric drug discovery, ... 2026-09-25T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Lundbeck to establish global innovation hub in Greater Boston and relocate US headquarters The new hub in Greater Boston will bring Lundbeck closer to one of the world's leading life sciences ecosystems, strengthening access to science, talent and partnerships. The move is part of Lundbeck's ... 2026-09-25T Biotechnology Health Care/Hospital Medical/Pharmaceuticals

PR Newswire Asia's news > Biotechnology